Revolutionising organ repair with an innate immunotherapy that offers a less-invasive alternative to liver transplantation. 

Advancing safer, more accessible cell therapies to improve outcomes for cancer patients. 

Turning the promise of genetic medicine into cures for peripheral nerve diseases, starting with Neurofibromatosis type 1.

Developing a data-driven discovery platform that unlocks new Therapy-induced Novel Antigens to power the next generation of targeted cancer therapeutics. 

Pioneering next generation microbiome therapies to tackle IBD and other complex gut disorders. 

Discovered and optimised first-in-class compounds across oncology and neurological disease, including a novel dual-action immuno-oncology programme designed to activate anti-tumour immunity while directly destroying tumour cells.  

Advancing next-generation CAR T-cell therapies to tackle the unmet needs of patients with sold tumours. 

Pioneering a child-first cancer gene therapy that reprogrammes tumour cells to trigger powerful immune responses. 

Developing next-generation microbiome-based therapies to improve skin health. 

Creating a safer, more effective therapy for hospitalised patients with life-threatening fungal infections. 

Building better biologics using advance synthetic chemistry. 

Using advanced computational models of bacteria to develop first-in-class antibacterial drugs.

Advancing AI-led aptamer design to create next-generation targeted therapeutics. 

Creating ML-powered cancer vaccines to improve precision and patient outcomes.

Developing next-generation MOF platforms for controlled, tumour-targeted delivery of radiopharmaceuticals and other therapeutics.

Creating a first-in-class virulence factor inhibitor that disarms Gram-negative bacteria to combat antimicrobial resistance.